GlassScriptPhysician profile
Lily K Sunio
NPI 1467683904
$3,717.19
in general payments reported to CMS, 2019-2025
25 companies · $670 in 2025
The $670 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $243 · 2021: $313 · 2022: $1,174 · 2023: $372 · 2024: $587 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606 · Education: $23.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.22 |
| Education | $23.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $553.53 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $509.02 | 2019-2025 | Farxiga |
| Mallinckrodt Hospital Products INC. | $399.74 | 2020-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $346.71 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $331.03 | 2019-2024 | Veltassa |
| Aurinia Pharma U.S., INC. | $216.45 | 2021-2024 | Lupkynis |
| Amgen INC. | $198.58 | 2019-2025 | Tavneos, Krystexxa |
| Mallinckrodt Enterprises LLC | $152.34 | 2019 | |
| Alexion Pharmaceuticals, INC. | $102.62 | 2019-2024 | Ultomiris |
| Travere Therapeutics, INC. | $97.74 | 2023-2025 | |
| Abbott Laboratories | $96.13 | 2025 | Proclaim |
| Nxstage Medical, INC. | $90.50 | 2021 | |
| Fresenius USA Marketing, INC. | $90.24 | 2022-2025 | Velphoro, Velphoro |
| Ardelyx, INC. | $86.03 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $81.55 | 2024-2025 | Tarpeyo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $72.79 | 2022-2025 | Benlysta |
| Baxter Healthcare | $47.17 | 2023 | Renal - Pd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.90 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $45.87 | 2022 | |
| Lilly USA, LLC | $35.44 | 2024-2025 | Jardiance |
| Apellis Pharmaceuticals, INC. | $29.48 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $26.33 | 2025 | |
| Novartis Pharmaceuticals Corporation | $26.14 | 2024 | |
| Horizon Therapeutics Plc | $18.10 | 2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $16.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Sunio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.